In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor
Top Cited Papers
- 26 January 2005
- journal article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 3 (3), 514-521
- https://doi.org/10.1111/j.1538-7836.2005.01166.x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- What is all that thrombin for?Journal of Thrombosis and Haemostasis, 2003
- Nonpeptide Factor Xa Inhibitors: DPC423, a Highly Potent and Orally Bioavailable Pyrazole Antithrombotic AgentCardiovascular Drug Reviews, 2002
- Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic RangeChest, 2001
- Managing Oral Anticoagulant TherapyChest, 2001
- Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in ratsEuropean Journal of Pharmacology, 1998
- Biochemical and Pharmacological Characterization of YM-60828, a Newly Synthesized and Orally Active Inhibitor of Human Factor XaThrombosis and Haemostasis, 1998
- Antithrombotic Activity of Argatroban in Experimental Thrombosis in the RabbitSeminars in Thrombosis and Hemostasis, 1996
- Antithrombotic actions of argatroban in rat models of venous, ‘mixed’ and arterial thrombosis, and its effects on the tail transection bleeding timeBritish Journal of Pharmacology, 1994
- Interactions of Warfarin with Drugs and FoodAnnals of Internal Medicine, 1994
- Synthetic substrates for human factor VIIa and factor VIIa-tissue factorBiochemistry, 1993